On December 6, 2021, leading experts from the SITC Hepatocellular Carcinoma Immunotherapy Guideline Expert Panel presented "Practical Management Pearls for Immunotherapy for the Treatment of Hepatocellular Carcinoma — SITC CPG Webinar." This high-level webinar was designed to teach attendees how to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease, as discussed in the Clinical Practice Guideline (CPG). The recorded webinar and presentation slides are available below.
Webinar Faculty:
Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, please visit connected.sitcancer.org, or check out our free CPG mobile app.
The Practical Management Pearls and Case Studies Webinars are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/15/2021).The SITC Clinical Practice Guidelines are produced by SITC and have no funding from outside sources.
Meeting: Practical Management Pearls for Immunotherapy for the Treatment of Hepatocellular Carcinoma – SITC CPG Webinar; Faculty: Ghassan Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center; Lisa H. Butterfield, PhD – Parker Institute for Cancer Immunotherapy and UC San Francisco; Richard S. Finn, MD – David Geffen School of Medicine at UCLA; Tim F. Greten, MD; Date: December 6, 202101:07:13
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us